Page 56 - Pharma Sector

USFDA observes major protocol lapses in Aurobindo's sterile drug unit

Regulator issues Form 483 with as many as 14 observations that could impact ongoing operations at the plant

Regulatory overhang may dent Aurobindo Pharma earnings estimate by 15-20%

The stock tanked to its five-year low before closing 8.7 per cent lower on Thursday

Pharma Q2 Preview: Lack of new US approvals to overshadow domestic revival

Analysts expect a 12% growth in revenues for the sector

Bills for pills: Antibiotics could be govt's next segment for price cap

Centre likely to consider rationalising trade margins

India's leading drugmakers stocking up to avoid supply disruptions

Have increased raw material buffer stock by at least 40 days in recent months

USFDA impact: DCGI asks states told to put antacids under scanner

The ranitidine market in India is roughly around Rs 700 crore, with about 180 brands

Biocon to set up R&D facility in India to boost biosimilars development

Biocon has acquired some assets from Pfizer Healthcare to set up its second R&D plant in India

Dr Reddy's Labs shines among pharma stocks, wins investor confidence

The Hyderabad-based company is an outlier among large pharmaceutical producers, having seen a jump in its stock price over the previous year

PE majors TPG, Temasek planning investments in Indian API manufacturers

The investment interest comes as Indian drugmakers are focusing on specialty products, while relying extensively on Chinese imports for basic ingredients and other raw materials used in medicines

300 fresh pharma unit applications up for approval in Gujarat: FDCA

As per the state FDCA commissioner, the state has benefited from the introduction of GST

Glenmark gets US health regulator nod for generic breast cancer injection

The product is a generic version of AstraZeneca Pharmaceuticals LP's Faslodex Injection in the same strength, the company said

From Dr Reddy's to Cipla, pharma companies aren't out of the woods: Experts

The Street is cautious given multiple challenges in core markets of US and India

Sun Pharma signs global licensing pact with CSIR-IICT for patents

The pact is for patents related to certain compounds with potential therapeutic activity across multiple indications

Unichem gets USFDA approval for high blood pressure drug Chlorthalidone

Unichem said the product will be commercialised from its Ghaziabad plant

At 13%, domestic pharma sales witness double-digit growth in July

Volume growth in the domestic market had turned negative in the last two months but was a big growth driver in July

Aurobindo Pharma gains nearly 8% on growth prospects in US market

The completion of Sandoz acquisition and new product launches are triggers

Aurobindo Q1 profit up 39.5% at Rs 636 crore on strong revenue growth

Revenue from operations rose 28.1% year-on-year to Rs 5,444.6 crore during the quarter under review

Fund managers bet on pharma sector as pricing pressure in US is stabilising

The Indian pharma sector has many attractive opportunities before it, such as the growing adoption of generic drugs in developed markets

Lupin gets Establishment Inspection Report from FDA for Aurangabad facility

The facility was inspected by the US Food and Drug Administration

Active pharmaceutical ingredients focus helps drug firms offset slowdown

Besides captive consumption, the company also supplies APIs to external customers across international markets